O
Omniscient Neurotechnology
Enterprise grade clinical and research solutions applicable to a variety of brain-related disorders
About Omniscient Neurotechnology
O8t.com, also known as Omniscient, operates in the healthcare technology sector, specifically focusing on neurology and brain health. The company's primary offering is a digital brain mapping solution, known as the connectome, which uses artificial intelligence (AI) and cloud computing to process vast quantities of neural data. This technology provides precise knowledge of a patient's unique brain networks, offering actionable insights for surgeons prior to life-changing surgeries.
The company's solutions are designed for a wide range of clients, including neurosurgeons, psychologists, and researchers. By providing a more robust understanding of the brain, Omniscient's tools aim to enhance the diagnosis and treatment of neurological conditions, thereby improving patient outcomes.
Omniscient's business model revolves around the development and sale of its brain mapping technology. The company generates revenue by partnering with healthcare institutions and professionals who utilize their technology for surgical planning and research purposes.
In addition to its commercial activities, Omniscient is also heavily involved in research and development. The company collaborates with top institutions worldwide to push the boundaries of brain health understanding and technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Sydney, Australia
- Employees
- 65
- Open positions
- 11
- Dealroom signal
- 80.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Predictive Analytics, Biotechnology, Drug Development, Neurology, Techbio, Hard Tech, DT and LS
- Technology
- Artificial Intelligence, Big Data, Deep Tech
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2026 | $27M | $445M | Gina Rinehart · Will Vicars · Australian National Reconstruction Fund | ↗ |
| SERIES COther financing | Jun 2024 | $58M | $230M | Will Vicars · Gina Rinehart | ↗ |
Growth signals
Latest recorded traffic for Omniscient Neurotechnology is 32K monthly website visits, up 28% over the last three months. Omniscient Neurotechnology's team grew 12.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- GRGina Rinehart
- GPGretel Packer
- KNKerr Neilson
- WVWill Vicars
Series B and later1 investor entered at this stage
Australian National Reconstruction Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Omniscient Neurotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Omniscient Neurotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.